BB: Medical science needs a way to objectively measure pain. This would be one of the circumstances where it would be extremely useful.
This migraine product is an opiate. When they allowed legal use of marijuana for people with glaucoma, people without glaucoma went out to hip doctors and got diagnosed as having glaucoma. Then it expanded to just about any medical reason conjured.
If your a big fan of marijuana, that is not a problem. But there aren't a lot of fans of heroin. It appears that this is what that hearing is all about. The governor of Massachusetts blocked sales of that Migraine relief product out of concerns that the situation could degenerate into wide, improper use. This legal action is bad news for people with migraines, but I can see why the governor did what he did. It is a bad situation.
Again, what they need is a way to objectively measure pain. Not sure it will every happen, but I think it might. Unfortunately, true pain goes all the way back to Descartes' little man in the theater. And he has alluded most of us, and certainly science. He has certainly alluded those that believe that computers will someday experience as humans do.
Nice to know other companies BB and LTT are investing in. But what I would really like to know is who Northwest Biotherapeutics is investing in. They say they are putting their recent $ gain into high yield securities while it awaits disbursement. Hope they didn't put it into Facebook or CDLX. I hope it was NWBO, but not sure if that would qualify as an insider move. Not sure if that would have to be publicized when it is not an individual insider doing the buying. It would be a stock buyback I suppose.
News 
Market Data 
Discover 
